Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

It is estimated that 10-15 million women use oral contraceptives in the U.S. The 2 types of pills available are combination products containing both an estrogen and progestin, and single entity products with only progestin. Although more side effects are associated with estrogen, combination pills are the preferred prescription. Most often side effects are mild and disappear after continued use or switching to another type of pill. Some of the side effects are nausea; weight gain; chloasma; cervical extrophia and leukorrhea; hypermenorrhea; spotting and breakthrough bleeding; galactorrhea and pituitary tumors; choreiform movement disorder; endometrial cancer; and, hepatic effects. Fetal exposure to exogenous estrogens and progestins has been reported to result in increased risk for the heart and neural tube defects. Teratogenic effects subsequent to discontinuation of OCs does not appear to be a risk. The beneficial side effects of oral contraceptives are that the incidence of menorrhagia, benign breast neoplasm, dysmenorrhea, iron-deficiency anemia, premenstrual tension, acne, and ovarian cysts are lower in OC users. Thryoid diseases may be reduced by OCs.
 ...
PMID:Side effects of oral contraceptives. 50 75

The beneficial effects of combined estrogen-progestin-containing oral contraceptives (OCs) include prevention of pregnancy (less than 1 failure out of 100 regular users); the prevention of ectopic pregnancy; the reduction of preeclampsia (2.4 times lower risk compared with barrier methods); and reduction of pelvic inflammation to about one-half. The effects on menstruation include the reduction of sideropenic anemia (by lowering the incidence and duration of menstruation, OCs reduce the loss of iron to 50% or to as much as 33%); dysmenorrhea by 40% (symptoms receded in 90% of users); and premenstrual syndrome by 30%. OCs exert a favorable effect on menstrual epilepsy; reduce sports-related accidents in the premenstrual and menstrual periods; and reduce intermenstrual bleeding. The protection from cancer includes the lowering of endometrial cancer risk (every 2 years of use reduces the risk by 38%, 12 years of use by 70%, and the beneficial effects last 3-15 years); reduction of the risk of the ovarian cancer (already 3-6 months of use reduces the risk by 30%, and more than 5 years by 50% in women under 50 years of age with a longterm effect of 10 years or more, which drops sharply in women over 60 who are mostly at risk). Among other beneficial effects, they reduce benign mastopathy by 50-75%; reduce the risk of follicular ovarian cysts to 50% and the risk of corpus luteal ovarian cysts to 1/5; and they lessen bone loss which favorably affects osteoporosis. Low-dose OCs minimize the well-known risks of thrombotic and cerebrovascular accidents, myocardial infarction, hypertension, altered carbohydrate metabolism, gallbladder diseases, and liver cancer. A new OC with 30 mcg of ethinyl estradiol was tested with daily doses of 150 mcg of desogestrel. The high density lipoprotein (HDL) either increased or did not change with desogestrel: the HDL2 subfraction that protects from atherosclerosis did not change, and probably the HDL3 raised the HDL level.
 ...
PMID:[Favorable effects of oral estrogen-progestin contraception]. 181 41

Contrast media in magnetic resonance imaging (MRI) of the abdomen and pelvis are applied for various purposes; different substances and forms of application must be distinguished. Oral contrast agents are primarily used to enhance the discrimination of the intestine from the other organs and from pathological lesions. Clinical studies of i.v. contrast agents focus on two substances: gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA) and superparamagnetic iron oxide. Whereas dynamic Gd-DTPA-enhanced MRI improves the differential diagnosis of focal hepatic lesions, iron oxide is a promising agent for increasing the sensitivity of MRI in the detection of hepatic and splenic tumors. Dynamic Gd-DTPA-enhanced MRI of the kidney allows functional assessment of this organ; good demarcation of kidney tumors is only achieved during the early phase of a dynamic examination. In the assessment of adrenal lesions, dynamic Gd-DTPA-enhanced MRI permits better differentiation of adenoma from malignancy. Intravenous Gd-DTPA also appears to be useful in the staging of urinary bladder tumors to distinguish between superficial and infiltrating tumors. Although offering no major diagnostic advantage in the staging of cervical carcinomas, Gd-DTPA-enhanced MRI improves the discrimination of necrotic tumor portions of endometrial carcinoma and allows good differentiation of this lesion from fluid retained in the uterine cavity. Studies of new contrast agents for MRI of the abdomen, which have so far only been investigated in animal experiments, focus on liver imaging. These substance include hepatobiliary agents, Gd-DTPA-containing liposomes, and paramagnetic macromolecules.
 ...
PMID:Contrast-enhanced magnetic resonance imaging of the abdomen and pelvis. 220 22

The new generation of oral contraceptives (OCs) contains less than 50 mcg of estrogen compared to previous levels of 100-150 mcg, and as a result have fewer undesirable side effects. In addition, it appears that the newer OCs decrease the susceptibility to many diseases. For example, the pill decreases by 40% the risk that a woman under 55 years of age will develop ovarian cancer. The risk of endometrial cancer is reduced by 50% in OC users. The pill also significantly lowers the risk of pelvic inflammatory disease--a condition that is involved in almost 20% of all gynecologic problems and is a leading cause of infertility. OC use reduces the risk of ectopic pregnancy. Further, by decreasing menstrual blood flow, the pill protects against iron-deficiency anemia. The pill is claimed to decrease premenstrual tension, menstrual cramps, and even acne. It has a protective effect against ovarian cysts and benign breast cancer. Finally, there is the possibility that OCs protect against the development of rheumatoid arthritis and duodenal ulcers.
 ...
PMID:Oral contraceptives come of age. 385 23

Nutritional parameters of patients with cervical cancer and endometrial cancer were prospectively evaluated. Analysis of anthropometric assessments that were abnormal in as many as 52% of patients indicated little difference between organ sites in mean values or percentage of patients with abnormal values. Biochemical parameters included serum albumin, total iron-binding capacity, copper, zinc, and creatinine height index. An abnormal value was present in as many as 60% of patients. Multiple abnormal values were more likely to be present in patients with endometrial cancer. Abnormal vitamin levels were more commonly present in patients with cervical cancer. When compared to control values, levels of plasma folate, beta carotene, and vitamin C were significantly lower in patients with cervical cancer. Patients with endometrial cancer had significantly lower levels of beta carotene and vitamin C. Analysis of surgical complications suggested a correlation with specific nutritional deficits.
 ...
PMID:Corpus and cervix cancer: a nutritional comparison. 393 76

The usefulness of oral contraceptives (OCs) has been fully reappraised in recent years, and numerous beneficial effects on general health have been demonstrated over and above contraceptive action. Examination of several prospective and retrospective epidemiological studies has pointed to a reduced incidence of ovarian functional cysts and ovarian carcinoma in women taking OCs. Dysmenorrhea and premenstrual tension are also diminished while the risk of iron-deficiency anemia is decreased by 50% owing to a reduction in menstrual flow. There is approximately a 50% reduction in endometrial carcinoma risk, coupled with a significant reduction in the incidence of benign breast diseases. OCs also offer protection against rheumatoid arthritis and pelvic inflammation. Lastly, it is pointed that fears concerning augmented risk for cardiovascular disease while on OCs have proven to be false alarms. (author's modified)
 ...
PMID:[Positive effects of oral contraceptives]. 668 43

Studies have documented the protective effects of oral contraceptives (OCs) against 5 diseases: 1) OCs prevent 50-75% of potential cases of benign breast disease; there is an estimated annual reduction of 235 hospitalized cases for every 100,000 U.S. women using OCs or about 20,000 hospitalizations each year. 2)OCs reduce the occurrence of retention cysts of the ovary; an estimated 3000 surgical procedures for ovarian cysts are prevented each year in the U.S. 3) OC users have approximately 45% less iron-deficiency anemia than nonusers due to less menstrual flow. 4) OCs protect against the development of pelvic inflammatory disease (PID); 600 of every 100,000 OC users are prevented from contracting a 1st episode of PID and 156 PID hospitalizations are averted for every 100,000 OC users annually. 5) OCs protect against ectopic pregnancy; approximately 120 hospitalizations/100,000 users are prevented annually. 3 additional diseases may be prevented by OCs, although the evidence is not as conclusive as for the 5 previously discussed; OC users are only 1/2 as likely to develop: 1) rheumatoid arthritis, 2) endometrial cancer, and 3) ovarian cancer as nonusers. OCs have also been shown to reduce the incidence of such disorders as excessive menstrual bleeding, irregular menses, intermenstrual bleeding, painful menstruation, and premenstrual tension.
 ...
PMID:The noncontraceptive health benefits from oral contraceptive use. 711 6

The noncontraceptive health benefits of oral contraceptives were initially summarized a decade ago. Studies conducted in the last decade confirmed the findings of earlier studies with high-dose oral contraceptives and extended them to low-dose formulations. Among the noncontraceptive health benefits first cited were reductions in menorrhagia, irregular menses, endometrial cancer, ovarian cancer, functional ovarian cysts, benign breast disease, dysmenorrhea, premenstrual tension and iron-deficiency anemia. In addition, women who used oral contraceptives were less likely to develop rheumatoid arthritis or acute salpingitis, particularly moderate or severe forms, than were women using no method of contraception. Despite the fact that such benefits were identified more than 10 years ago and despite their inclusion in oral contraceptive labeling, women today are largely unaware of the noncontraceptive health benefits associated with oral contraceptive use.
 ...
PMID:Noncontraceptive benefits of oral contraceptives. 812 Aug 59

This paper reviews the noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate (DMPA). Relevant articles were reviewed using a computerized Medline search of the literature from 1966 to 1995. Good evidence shows that DMPA use is associated with reduced iron-deficiency anemia, protection against pelvic inflammatory disease, protection from endometrial cancer and improved hematologic parameters among users with sickle cell disease. More studies are needed to fully assess DMPA's impact on other disorders.
 ...
PMID:Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate. 872 6

A sizeable literature corroborates the multiple health benefits of oral contraceptive use. The first estrogen/progestin combination pills were marketed to treat a variety of menstrual disorders. Although currently used oral contraceptives no longer carry FDA-approved labeling for these indications, they remain important therapeutic options for a variety of gynecologic conditions. Well-established gynecologic benefits include a reduction in dysmenorrhea and menorrhagia, iron-deficiency anemia, ectopic pregnancy, and PID. Although older, higher-dose pills reduced the incidence of ovarian cysts, low-dose pills suppress follicular activity less consistently. Nevertheless, cycle-related symptoms, including functional cysts, dysmenorrhea, chronic pelvic pain, and ovulation pain (mittelschmerz), generally improve. Women with polycystic ovary syndrome note improvement in bleeding patterns and a reduction in acne and hirsutism. Symptoms from endometriosis also improve with oral contraceptive therapy. Current data suggest that oral contraceptive therapy increases bone density and that past use decreases fracture risk. Oral contraceptives also improve acne, a major health concern of young women. Oral contraceptives provide lasting reduction in the risk of two serious gynecologic malignancies--ovarian and endometrial cancer. The data with respect to ovarian cancer are compelling enough to recommend the use of oral contraceptives to women at high risk by virtue of family history, positive carrier status of the BRCA mutations, or nulliparity, even if contraception is not required. Health care providers must counsel women regarding these benefits to counteract deeply held public attitudes and misconceptions regarding oral contraceptive use. Messages should focus on topics of interest to particular groups of women. The fact that oral contraceptives increase bone mineral density and reduce ovarian cancer is of great interest to women in their forties and helps influence use and compliance in this group. In contrast, the beneficial effects of oral contraceptives on acne resonates with younger women. Getting the good news out about the benefits of oral contraceptives will enable more women to take advantage of their positive health effects.
 ...
PMID:Health benefits of oral contraceptives. 1109 85


1 2 Next >>